Company intelligence / Profile preview

Onset Dermatologics

Cumberland/Cumberland area, Rhode Island, United Statesonsettx.com ↗

Ownership: Private
Development stage: Other

Overview

Onset marketed a portfolio of prescription dermatology products based on proprietary foam and hydrogel technologies. Clinical results included significant reduction of itch in atopic dermatitis patients using Aurstat® Hydrogel. The company’s pipeline included both marketed products and investigational drugs for acne and other skin disorders.

Therapeutic areas: Dermatology
Modalities: Topical therapiesEmollient foamsHydrogels
Industry: Biotech

Partnerships

Oculus Innovative Sciences—commercial partnership to co-develop Microcyn-based dermatological therapies targeting atopic dermatitis and related conditions

Beyond the preview

Go deeper on Onset Dermatologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onset Dermatologics.